Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Chunmeng Wang, Master
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
Study Director - Hejin Jia, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
Principal Investigator - Jing Nie, Doctor
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
Study Director - Jingdan Qiu, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
Principal Investigator - Kaichao Feng, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
Principal Investigator - Liang Dong, Master
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
Principal Investigator - Lu Shi, Master
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
Principal Investigator - Meixia Chen, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
Study Director - Qian Mei, Doctor
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
Study Director - Wenying Zhang, Master
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
Study Director - Xiang Li, Master
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
Principal Investigator - Yan Zhang, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
Principal Investigator - Yang Liu, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Biotherapeutic Department of Chinese Pla General Hospital
Beijing, Beijing Municipality, China
Chunmeng Wang, MasterHejin Jia, DoctorJing Nie, DoctorJingdan Qiu, DoctorKaichao Feng, DoctorLiang Dong, MasterLu Shi, MasterMeixia Chen, DoctorQian Mei, DoctorQingming Yang, DoctorWeidong Han, DoctorWenying Zhang, MasterXiang Li, MasterYan Zhang, DoctorYang Liu, DoctorRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2016
- Primary completion
- 31 May 2026
- Completion
- 31 May 2026
- Last update posted
- 22 Jan 2026
- Registered enrollment
- 250
- Registry id
- NCT02961101
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.